A prospective, observational study of rivaroxaban for stroke prevention in atrial fibrillation: the XANAP Korea

Jaemin SHIM; Young-Keun ON; Sun-U. KWON; Gi-Byoung NAM; Moon-Hyoung LEE; Hyung-Wook PARK; Keun-Sik HONG; Nam-Ho KIM; Pierre AMARENCO; Seung-Woon RHA; Dong-Gu SHIN; Joung-Ho RHA; Young-Hoon KIM.
The Korean Journal of Internal Medicine ; : 906-913, 2021.
Artículo en Inglés | WPRIM | ID: wpr-903665

Documentos relacionados

  1. A prospective, observational study of rivaroxaban for stroke prevention in atrial fibrillation: the XANAP Korea.
  2. A prospective, observational study of rivaroxaban for stroke prevention in atrial fibrillation: the XANAP Korea
  3. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.
  4. Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS.
  5. Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings.
  6. [Improved stroke prevention in atrial fibrillation: the Stockholm experience of the introduction of NOACs].
  7. [Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
  8. [Rivaroxaban in non valvular atrial fibrillation: subgroups analysis].
  9. XaMINA: A Real-World, Prospective, Observational Study of Treatment-Naïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia.
  10. [Real life clinical management of nonvalvular atrial fibrillation: results from the Italian epidemiological survey eXperience on the use of rivaroxaban].